SpinalCyte, LLC

49 articles about SpinalCyte, LLC

• SpinalCyte to Present at the 2019 BIO Investor Forum

  10/21/2019

  SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced that Pete O'Heeron, SpinalCyte's Chief Executive Officer, will present at the BIO Investor Forum on Tuesday, October 22, 2019 at 3:45 p.m. PDT in San Francisco, CA.

• SpinalCyte Launches Initiative to Highlight Advances in Fibroblast Technology

  5/15/2019

  SpinalCyte, LLC announced a new comprehensive resource to raise awareness of the potential benefits of fibroblasts and provide a growing knowledge base for this promising regenerative medicine technology.

• SpinalCyte to Provide Clinical Trial Update at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting

  3/28/2019

  SpinalCyte, LLC announced that Thomas Ichim, Ph.D., SpinalCyte’s Chief Scientific Officer, will present at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting on Thursday, April 4, 2019 at 7:50 a.m. PDT in Anaheim, CA.

• SpinalCyte to Present at China Focus @ Europe Vienna

  3/18/2019

  SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced that Pete O’Heeron, SpinalCyte’s Chief Executive Officer, will present at the China Focus @ Europe Vienna on Wednesday, March 27, 2019 at 3:00 PM CET in Vienna, Austria.

• SpinalCyte Announces New Chondrocyte Patents

  3/11/2019

  The company received IND clearance from the FDA in November to continue clinical trials into its lead fibroblast cell therapy product, CybroCell, in the treatment of degenerative disc disease.

• SpinalCyte Announces New Canadian Patent

  2/11/2019

  The company received IND clearance from the FDA in November to continue clinical trials into its lead fibroblast cell therapy product, CybroCell, in the treatment of degenerative disc disease.

• SpinalCyte to Present at the 2019 BIO CEO & Investor Conference

  2/4/2019

  SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced that Pete O'Heeron, SpinalCyte's Chief Executive Officer, will present at the BIO CEO & Investor Conference on Tuesday, Feb. 12, 2019 at 1:15 a.m. EST in New York, NY.

• SpinalCyte, LLC Announces New International Patent

  1/8/2019

  Patent further advances company’s commanding intellectual property position in fibroblast cell treatments

• FDA Clears SpinalCyte IND Application for Universal Donor Cell Therapy to Treat Lower Back Pain

  11/28/2018

  SpinalCyte, LLC a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced the FDA has cleared its Investigational New Drug (IND) protocol for human trials in the U.S., considered to be the first IND approval for a fibroblast cell therapy in a chronic condition outside of dermatological uses.

• SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection

  11/14/2018

  Data Shows Significant Improvement in Clinically Relevant Endpoints

• SpinalCyte Announces New International Patents

  11/7/2018

  Patents Enhance Company’s Position as the Leader in Spinal Cell Therapy

• SpinalCyte Announces Positive 12 Month Pain Data From Phase 1/Phase 2 Clinical Trial for Degenerative Disc Disease

  10/25/2018

  Pain Relief from CybroCell™ Dermal Fibroblasts Could Eliminate Need for Opioids in Some Patients

• SpinalCyte Announces Publication Supporting the Therapeutic Effects of Fibroblast Cell Therapy in Disc Degeneration and Inflammation in The Spine Journal

  10/11/2018

  SpinalCyte, LLC today announced the publication of results from its study on using cell transplantation as a cell therapy for disc degeneration.

• SpinalCyte to Feature Fibroblast-Based Cell Therapy Results at the 2018 North American Spine Society Annual Meeting

  9/24/2018

  SpinalCyte, LLC today announced it will be showcasing its fibroblast-based cell therapy product CybroCell at the North American Spine Society (NASS) 2018 Annual Meeting Sept. 26 - 29 in Los Angeles.

• SpinalCyte, LLC Announces New U.S. Patent No. 10,052,410

  8/28/2018

  SpinalCyte, LLC, today announced issuance of U.S. Patent No. 10,052,410, “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.”

• SpinalCyte Announces Publication of Fibroblast Cell Therapy Review in the Journal of Translational Medicine

  7/31/2018

  Showcases practicality of fibroblasts as an alternative to stem cells

• SpinalCyte Applies with FDA to Expand Human Clinical Trial of CybroCell™ Dermal Fibroblasts as Investigational New Drug (IND)

  4/12/2018

  SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using Human Dermal Fibroblasts, has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to expand its study of CybroCell Human Dermal Fibroblasts to treat degenerative disc disease.

• SpinalCyte Announces MRI Evidence of Disc Regeneration Following Phase 1/Phase 2 Clinical Trial of CybroCell™ Dermal Fibroblasts

  4/3/2018

  MRI Evidence of Increased Disc Height Could Eliminate Need for Opioids in Some Patients

• Phase I/II Clinical Trial Results Positive for SpinalCyte’s CybroCell Dermal Fibroblasts

  2/13/2018

  SpinalCyte’s Phase 1/2 trial is the first allogeneic use of fibroblasts outside of skin conditions.

• SpinalCyte, LLC Announces 25th Patent

  12/28/2017

  The company has received confirmation of the issuance of European Patent No. 2776556, “Fibroblasts For Treatment Of Degenerative Disc Disease.”